- Home
- DXR vs CTSO Comparison
DXR vs CTSO Comparison
Compare DXR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- CTSO
- Stock Information
- Founded
- DXR 1970
- CTSO 1997
- Country
- DXR United States
- CTSO United States
- Employees
- DXR N/A
- CTSO N/A
- Industry
- DXR Medical/Dental Instruments
- CTSO Medical/Dental Instruments
- Sector
- DXR Health Care
- CTSO Health Care
- Exchange
- DXR Nasdaq
- CTSO Nasdaq
- Market Cap
- DXR 42.6M
- CTSO 48.2M
- IPO Year
- DXR N/A
- CTSO N/A
- Fundamental
- Price
- DXR $8.24
- CTSO $0.92
- Analyst Decision
- DXR Strong Buy
- CTSO Strong Buy
- Analyst Count
- DXR 1
- CTSO 3
- Target Price
- DXR $24.75
- CTSO $4.67
- AVG Volume (30 Days)
- DXR 23.0K
- CTSO 141.5K
- Earning Date
- DXR 01-01-0001
- CTSO 11-07-2024
- Dividend Yield
- DXR N/A
- CTSO N/A
- EPS Growth
- DXR N/A
- CTSO N/A
- EPS
- DXR 0.35
- CTSO N/A
- Revenue
- DXR $154,205.00
- CTSO $37,739,531.00
- Revenue This Year
- DXR N/A
- CTSO $8.08
- Revenue Next Year
- DXR N/A
- CTSO $12.80
- P/E Ratio
- DXR $23.96
- CTSO N/A
- Revenue Growth
- DXR N/A
- CTSO 1.80
- 52 Week Low
- DXR $7.19
- CTSO $0.70
- 52 Week High
- DXR $10.04
- CTSO $1.88
- Technical
- Relative Strength Index (RSI)
- DXR 40.06
- CTSO 49.38
- Support Level
- DXR $8.04
- CTSO $0.80
- Resistance Level
- DXR $8.42
- CTSO $1.09
- Average True Range (ATR)
- DXR 0.36
- CTSO 0.09
- MACD
- DXR -0.09
- CTSO 0.00
- Stochastic Oscillator
- DXR 14.47
- CTSO 39.24
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.